The EESC issues between 160 and 190 opinions and information reports a year.
It also organises several annual initiatives and events with a focus on civil society and citizens’ participation such as the Civil Society Prize, the Civil Society Days, the Your Europe, Your Say youth plenary and the ECI Day.
Here you can find news and information about the EESC'swork, including its social media accounts, the EESC Info newsletter, photo galleries and videos.
The EESC brings together representatives from all areas of organised civil society, who give their independent advice on EU policies and legislation. The EESC's326 Members are organised into three groups: Employers, Workers and Various Interests.
The EESC has six sections, specialising in concrete topics of relevance to the citizens of the European Union, ranging from social to economic affairs, energy, environment, external relations or the internal market.
Current legislation requires N2 vehicles to be equipped with speed‑limitation devices, a rule originally designed for heavy‑duty vehicles to ensure road safety and environmental protection. Electric vans, however, often fall into the N2 category solely due to their battery weight. The exemption aims to align electric vans with their fossil‑fuel equivalents and support the transition to cleaner transport.
This opinion is prepared at the request of the incoming Cypriot Presidency of the EU. The EESC was invited to deliver an opinion on how the EU and its Member States can best:
1. Introduce and promote effective tools, including AI-based solutions, to enhance the quality of employment and working conditions, ensuring transparency, fairness, and accountability in their use.
2. Strengthen social dialogue and collective bargaining as fundamental mechanisms for shaping fair and inclusive labour markets in a rapidly changing economic and technological context.
The upcoming Cyprus Presidency of the Council of the EU has asked the EESC to draw up an exploratory opinion aimed at providing insight and recommendation on the establishment of the European centre of clinical excellence for pharmaceuticals, with the view to serve as a unified, evidence-based authority issuing pharmacotherapy recommendations, guidelines, and protocols for a wide range of diseases.